Axonyx’ Phenserine Fails Pivotal Alzheimer’s Trial Due To High Placebo Response

Development program for the potential disease-modifying Alzheimer’s agent will continue, the firm says. A second pivotal trial began in June 2004. Interim results from a Phase IIb mechanistic study are expected in March.